Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal ... - Marketscreener.com

Melinta Therapeutics, LLC and Cidara Therapeutics, Inc. announced the peer-reviewed publication of pooled data from two completed global clinical trials evaluating REZZAYO®? (rezafungin for injection) for the treatment of candidemia and invasive candidiasis. The article, "Efficacy and safety of rezafungin and caspofungin in candidemia and invasive candidiasis: pooled data from two prospective randomised controlled trials," published in The Lancet Infectious Diseases, reports on pooled data analyses of the pivotal ReSTORE Phase 3 randomized controlled clinical trial, which demonstrated the non-inferiority of rezafungin versus caspofungin for all-cause mortality and with similar safety profiles and provide additional evidence for potential early treatment benefits.

marketscreener.com     Dec 05, 2023